The US Food and Drug Administration (FDA) has approved an improved stool collection kit of Geneoscopy’s RNA-based colorectal ...

The earnings release highlighted strong GAAP revenue growth that beat consensus estimates, adjusted earnings per share (non-GAAP) that outpaced expectations, and an increase in adjusted operating ...

Raises Full-Year Guidance Financial results from Operations for second quarter 2025 versus second quarter 2024: Revenue: $3.53 billion versus $3.22 billion ...

We primarily deployed the proceeds from selling Nilorn into Havas in the first quarter and into Fortrea during the second ...